Ready-to-use Sodium Phosphates Injection Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sodium phosphate solutions for intravenous administration in treating hypophosphatemia are prone to cardiac and pulmonary risks due to incorrect concentration and infusion rate, require aseptic compounding, and have stability issues with aluminum toxicity and crystallization, necessitating a stable, ready-to-use formulation with reduced aluminum content.
Innovation Solution
Development of a ready-to-use, sterile, isotonic or hyper-isotonic Sodium Phosphates Injection solution with a suitable phosphate-to-sodium ratio and aluminum content ≤50 mcg/L, packaged in a flexible polyolefin container, providing extended storage stability and eliminating the need for dilution or manipulation before administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If concentrated sodium phosphate solutions are used for intravenous administration, then the infusion rate can be adjusted to patient need, but serious cardiac reactions and pulmonary embolisms may occur due to incorrect concentration and infusion rate
Solution Approach 1:
The patent changes the concentration parameter from concentrated solutions to ready-to-use diluted solutions with standardized phosphorus concentrations (15 mmol/100 mL or 1.5 mmol/100 mL). This parameter change eliminates the need for infusion rate calculations and adjustments, directly preventing cardiac reactions and pulmonary embolisms caused by incorrect concentration administration
2Duration of action of stationary object
If concentrated sodium phosphate solutions are used, then storage is simplified, but crystallization and precipitation occur after limited exposure to oxygen
Solution Approach 1:
The patent changes the concentration parameter by providing ready-to-use diluted solutions instead of concentrated solutions. This parameter change fundamentally resolves the stability issue: diluted solutions do not undergo crystallization or precipitation even after extended storage periods, eliminating the time limit on storage duration that plagues concentrated solutions
3Quantity of substance
If concentrated sodium phosphate solutions are used, then the solution volume is reduced, but aseptic compounding is required increasing contamination risk
Solution Approach 1:
The patent applies preliminary action by pre-diluting the sodium phosphate to ready-to-use concentrations during manufacturing. This preliminary dilution action eliminates the need for aseptic compounding at the point of use, as the solutions are already at appropriate concentrations for direct administration. The ready-to-use packaging maintains sterility while eliminating contamination risks associated with bedside compounding
4Adaptability or versatility
If separate preparations are made for central and peripheral venous administrations, then the dosage can be optimized for each route, but the preparation time and complexity increase
Solution Approach 1:
The patent applies universality by formulating ready-to-use sodium phosphate solutions with standardized phosphorus concentrations that are suitable for both central and peripheral venous administrations. This universal formulation eliminates the need for separate preparations for different administration routes, reducing preparation time and complexity while maintaining dosage appropriateness for both routes
5Quantity of substance
If currently approved sodium phosphate products are used, then phosphorus replacement therapy can be provided, but aluminum toxicity may occur in patients with renal impairment
Solution Approach 1:
The patent applies the extraction principle by removing aluminum from the sodium phosphate formulation. The ready-to-use solutions are specifically formulated with reduced aluminum content to prevent aluminum toxicity in patients with renal impairment, while maintaining adequate phosphorus replacement therapy. This selective removal of the harmful aluminum component resolves the contradiction between providing phosphorus therapy and preventing aluminum toxicity
Data Source
AI summary
Ready-to-use (RTU) Sodium Phosphates solutions for phosphorus replacement therapy are presented that include Sodium phosphate with/without sodium chloride at a fixed volume with 1.5 to 15 mmol/100 mL phosphorus, no more than 20 mEq/100 mL Sodium and less than 50 mcg/L aluminum.